Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Jul 2023

Sadras Ido, Cohen-Cymberknoh Malena, Kerem Eitan, Koplewitz Benjamin Z, Simanovsky Natalia, Wilschanski Michael, Birimberg-Schwartz Liron, Breuer Oded

Abstract excerpt

Cystic fibrosis transmembrane conductance regulator modulator therapy is associated with substantial clinical benefit and improved quality of life in patients with cystic fibrosis (CF). While their effect on lung function has been clearly reported, we are still in the process of unraveling the full impact they have on the pancreas. We present two cases of pancreatic-insufficient CF patients who presented with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Aminophenols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Pancreatitis

Share to Quality of Life

Source

Identifiers

PMID: 36914434
DOI: 10.1016/j.jcf.2023.02.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators.PMID 36914434Read ↗

CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis.Semantic proximity Read ↗

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review.Semantic proximity Read ↗

Pancreatic complications in children with cystic fibrosis.Semantic proximity Read ↗

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control StudySemantic proximity Read ↗

Elexacaftor-Tezacaftor-Ivacaftor As A Final Frontier in The Treatment of Cystic Fibrosis: Definition of The Clinical and Microbiological Implications in A Case-Control StudySemantic proximity Read ↗

Current clinical opinion on CFTR dysfunction and patient risk of pancreatitis: diagnostic and therapeutic considerations.Semantic proximity Read ↗

Idiopathic chronic pancreatitis treated with ivacaftor in a CFTR carrier with methylmalonic acidemia.Semantic proximity Read ↗

Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.Semantic proximity Read ↗

Differential Expression and Microsystem Physiology Reveal Predominant and Drug Reversible CFTR-Related Defects in Idiopathic PancreatitisSemantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.Semantic proximity Read ↗

CFTR function is impaired in a subset of patients with pancreatitis carrying rare CFTR variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.